Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice

  • Authors:
    • Shun Lu
    • Jie Zhang
    • Zhen Zhou
    • Mei-Lin Liao
    • Wei-Zhong He
    • Xiao-Yan Zhou
    • Zi-Ming Li
    • Jia-Qing Xiang
    • Jie-Jun Wang
    • Hai-Quan Chen
  • View Affiliations

  • Published online on: September 1, 2008     https://doi.org/10.3892/or_00000045
  • Pages: 581-587
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Zoledronic acid (Zometa, ZOL) and cytotoxic chemotherapy agents have been reported to have synergistic antitumor activities. However, there is limited data on the effects of combination therapies on the development of bone metastasis in animal models of lung cancer. The purpose of this study was to establish a human lung adenocarcinoma cell line with high bone metastatic potential in an immunodeficient mouse model and to evaluate the synergistic inhibitory activity of zoledronate and paclitaxel (P) on bone metastasis in nude mice. A human lung adenocarcinoma cell line with high bone metastatic potential (SPC-A1-BM) was established by 10 rounds of in vivo selection. Cells were inoculated into the cardiac ventricle of NIH-BNX mice, which were treated 8 days later with: ZOL (0.2 mg/kg s.c. twice weekly) alone, P (6.0 mg/kg every week, i.p.) alone, P + ZOL, or vehicle (10 mice per group). Tumor growth was evaluated with bone scans, X-rays and in situ immunohistochemistry. Serum n-telopeptide of type I collagen (NTX) was measured by ELISA. Survival was assessed using the Kaplan-Meier method. Bone scan, radiographic and histological assessments revealed fewer bone metastases in all treatment groups vs. vehicle, with P + ZOL significantly reducing the incidence of bone metastases detected by bone scans (P=0.020) and X-rays (P=0.036). A histological analysis revealed marginal differences in the number of bone metastases between P + ZOL and vehicle (P=0.058). There was a trend towards differences in survival between the groups (P=0.1511) and survival was significantly longer for the P + ZOL group vs. vehicle (P=0.022). Compared with vehicle and ZOL alone, cancerous cells in the bone of mice treated with P + ZOL expressed higher levels of Bax and lower levels of Bcl-2 and Bcl-xl. ZOL produced a trend towards reduced NTX levels vs. vehicle and P + ZOL produced a profound reduction in NTX vs. vehicle (P=0.022). The results of this study indicated that zoledronate enhanced the efficacy of paclitaxel synergistically, by reducing the incidence of bone metastasis from lung cancer and prolonging survival in a mouse model of non-small cell lung cancer with a high potential for metastasis to bone.

Related Articles

Journal Cover

September 2008
Volume 20 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu S, Zhang J, Zhou Z, Liao M, He W, Zhou X, Li Z, Xiang J, Wang J, Chen H, Chen H, et al: Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep 20: 581-587, 2008.
APA
Lu, S., Zhang, J., Zhou, Z., Liao, M., He, W., Zhou, X. ... Chen, H. (2008). Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncology Reports, 20, 581-587. https://doi.org/10.3892/or_00000045
MLA
Lu, S., Zhang, J., Zhou, Z., Liao, M., He, W., Zhou, X., Li, Z., Xiang, J., Wang, J., Chen, H."Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice". Oncology Reports 20.3 (2008): 581-587.
Chicago
Lu, S., Zhang, J., Zhou, Z., Liao, M., He, W., Zhou, X., Li, Z., Xiang, J., Wang, J., Chen, H."Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice". Oncology Reports 20, no. 3 (2008): 581-587. https://doi.org/10.3892/or_00000045